Lee Financial’s Corcept Therapeutics CORT Stock Holding History

Lee Financial’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-750	Closed	-$14K	–	475
2017 Q3	$14K	Buy	+750	New	+$11.2K	﹤0.01%	279

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Lee Financial's CORT Position: Q4 2017 in Review

Lee Financial sold out of Corcept Therapeutics (CORT) in Q4 2017, closing a stake of 750 shares — an estimated $14K sold.

Lee Financial first reported a position in CORT in Q3 2017 and held it in 1 quarter. The position peaked at $14K in Q3 2017. 190 funds tracked by Wall St. Rank hold CORT as of Q4 2017.

Lee Financial reported no remaining Corcept Therapeutics position as of Q4 2017 after selling out during the quarter.
Lee Financial sold 750 Corcept Therapeutics shares in Q4 2017, an estimated $14K.
Lee Financial first reported a position in Corcept Therapeutics in Q3 2017 and held it in 1 quarter.
Lee Financial's Corcept Therapeutics position peaked at $14K in Q3 2017.
190 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2017.

Based on Lee Financial's 13F filing for Q4 2017, filed 9 Feb 2018.